Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification
- PMID: 22176384
- DOI: 10.1111/j.1365-2036.2011.04948.x
Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification
Abstract
Background: In irritable bowel syndrome (IBS) subtyping is used in research and clinical practice. Knowledge of subtype stability is needed for proper design of trials and treatment strategies.
Aims: To evaluate the stability of Rome III IBS subtypes over time and to determine the optimal time period for prospective, diary-based subtyping.
Methods: Rome III IBS patients aged 18-70 years enrolled in two identical, randomised, placebo-controlled trials of probiotics, were included. No difference was found on stool pattern, thus patients were analysed as one group. Patients scored defaecations according to Bristol Stool Form Scale for 10 weeks. IBS subtypes were determined for all 1- and 2-week periods. Subtype distribution and stool pattern over time were determined. The proportions of patients having the same subtype all weeks (stable patients) or having a predominant subtype (same subtype ≥60% of time) were determined.
Results: A total of 126 patients, mean age 46 ± 15 years, 72% women were included. Subtype distribution was similar over time with IBS with constipation, IBS with diarrhoea and IBS unsubtyped constituting one-third of the population each. Even though only 18-35% had the same subtype all weeks, the majority of patients had the same subtype for ≥60% of time (82-98%). Sixty-nine per cent had the same predominant and baseline subtypes. Two-week data increased the proportion of stable patients, of patients with a predominant subtype, and of patients who had similar baseline and predominant subtype.
Conclusions: Most IBS patients change subtype over time. However, an underlying stool pattern stability was demonstrated in the majority of patients. To increase stability, we recommend 2-week data for IBS subtyping.
© 2011 Blackwell Publishing Ltd.
Comment in
-
Commentary: short-term stability of subtypes in the irritable bowel syndrome.Aliment Pharmacol Ther. 2012 Apr;35(7):849-50; discussion 850-1. doi: 10.1111/j.1365-2036.2012.05004.x. Aliment Pharmacol Ther. 2012. PMID: 22404408 No abstract available.
Similar articles
-
Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.Aliment Pharmacol Ther. 2007 Sep 15;26(6):953-61. doi: 10.1111/j.1365-2036.2007.03422.x. Aliment Pharmacol Ther. 2007. PMID: 17767480
-
Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.J Gastroenterol Hepatol. 2012 Apr;27(4):760-5. doi: 10.1111/j.1440-1746.2011.06930.x. J Gastroenterol Hepatol. 2012. PMID: 21929652
-
Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study).Aliment Pharmacol Ther. 2007 Feb 1;25(3):323-32. doi: 10.1111/j.1365-2036.2006.03197.x. Epub 2007 Jan 8. Aliment Pharmacol Ther. 2007. PMID: 17217445
-
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.Curr Med Res Opin. 2013 Feb;29(2):149-60. doi: 10.1185/03007995.2012.754743. Epub 2012 Dec 20. Curr Med Res Opin. 2013. PMID: 23198977 Review.
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
Cited by
-
Strategies for Producing Low FODMAPs Foodstuffs: Challenges and Perspectives.Foods. 2023 Feb 17;12(4):856. doi: 10.3390/foods12040856. Foods. 2023. PMID: 36832931 Free PMC article. Review.
-
Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.BMC Gastroenterol. 2019 May 7;19(1):69. doi: 10.1186/s12876-019-0985-1. BMC Gastroenterol. 2019. PMID: 31064345 Free PMC article.
-
Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.Dig Dis Sci. 2017 Jun;62(6):1480-1485. doi: 10.1007/s10620-017-4585-z. Epub 2017 Apr 27. Dig Dis Sci. 2017. PMID: 28451914
-
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016. Int J Gen Med. 2016. PMID: 26929659 Free PMC article. Review.
-
Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome.World J Gastroenterol. 2018 Jan 21;24(3):338-350. doi: 10.3748/wjg.v24.i3.338. World J Gastroenterol. 2018. PMID: 29391756 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources